The Canadian Children Inflammatory Bowel Disease Network (CIDsCaNN)
CIDsCaNN
1 other identifier
observational
2,400
1 country
12
Brief Summary
The CIDsCaNN Network is being established with the major goals of identifying why IBD develops so commonly in children and adolescents living in Canada, and of determining the best treatment strategies for different types of IBD. Focusing on a prospective, inception cohort of Canadian children of widely varied racial origins provides a unique opportunity to explore environmental risk factors early in life and close in time to disease onset, their influence on the host microbiome, and in the context of genetic susceptibility. In keeping with current treatment targets, assessed outcomes will include not only symptom resolution and growth, but also intestinal healing. We aim to identify best practice and to institute processes for continual improvement in care nationally.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2013
Longer than P75 for all trials
12 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2013
CompletedFirst Submitted
Initial submission to the registry
October 29, 2013
CompletedFirst Posted
Study publicly available on registry
December 5, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2026
CompletedMarch 20, 2024
March 1, 2024
12.6 years
October 29, 2013
March 18, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Sustained Clinical Remission
Primary outcome: To test the research hypothesis, the primary endpoint is sustained clinical remission, as defined for CD by PCDAI \<10 and for UC as PUCAI \< 10 at each of the 6, 12, and 18 month visits AND physician global assessment of interval disease severity as quiescent at each of these visits. This primary endpoint will be assessed at 18 months, although it is the intent of the network to continue evaluations of the cohort until transfer to adult care.
18 months after enrollment onto study
Secondary Outcomes (1)
Other Clinical Outcomes (combination of Pediatric Crohn's Disease Activity Index, Pediatric Ulcerative Colitis Activity Index, physician global assessment of disease activity, serologic inflammatory markers and fecal calprotectin results)
18 months after initial enrollment onto study
Other Outcomes (1)
Assessment of Intestinal Healing
18 months after initial enrollment onto study
Eligibility Criteria
The network will enroll all children and adolescents diagnosed with IBD - Crohn's, Ulcerative Colitis or inflammatory bowel disease undefined (Paris A1a or A1b definitions of age at diagnosis) at participating sites.
You may qualify if:
- diagnosed with IBD - Crohn's, ulcerative colitis or inflammatory bowel disease undefined
You may not qualify if:
- Refusal to give informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- The Hospital for Sick Childrenlead
- Children's Hospital of Eastern Ontariocollaborator
- British Columbia Children's Hospitalcollaborator
- Alberta Children's Hospitalcollaborator
- Stollery Children's Hospitalcollaborator
- IWK Health Centrecollaborator
- Montreal Children's Hospital of the MUHCcollaborator
- St. Justine's Hospitalcollaborator
- Health Sciences Centre, Winnipeg, Manitobacollaborator
- Eastern Healthcollaborator
- Children's Hospital of Western Ontariocollaborator
- McMaster Children's Hospitalcollaborator
Study Sites (12)
Alberta Children'S Hospital
Calgary, Alberta, T3B 6A8, Canada
Stollery Children'S Hospital
Edmonton, Alberta, T6G 2B7, Canada
Children'S Hospital of Bc
Vancouver, British Columbia, V6H 3N1, Canada
Winnipeg Children'S Hospital
Winnipeg, Manitoba, R3E 3P4, Canada
Janeway Children'S Health & Rehabilitation Centre
St. John's, Newfoundland and Labrador, A1B 3V6, Canada
Izaak Walton Killam Hospital (Iwk)
Halifax, Nova Scotia, B3K 6R8, Canada
Hamilton Health Sciences
Hamilton, Ontario, L8L8E7, Canada
CHILDRENS HOSPITAL OF WESTERN ONTARIO, Lawson Health Research Institute
London, Ontario, N6C2R5, Canada
Children's Hospital of Eastern Ontario (CHEO)
Ottawa, Ontario, K1H 8L1, Canada
SickKids Hospital
Toronto, Ontario, M5G 1X8, Canada
Montreal Children'S Hospital
Montreal, Quebec, H3H 1P3, Canada
Hopital Ste. Justine
Montreal, Quebec, H3T 1C5, Canada
Biospecimen
Blood samples Stool samples Biopsy Samples Colonoscopy Washing Samples Colonoscopy Brushing Samples Resection Tissue Urine Samples
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Anne M Griffiths, MD, FRCPC
The Hospital for Sick Children
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 144 Months
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Division Head, Gastroenterology, Hepathology and Nutrition
Study Record Dates
First Submitted
October 29, 2013
First Posted
December 5, 2014
Study Start
September 1, 2013
Primary Completion
April 1, 2026
Study Completion
April 1, 2026
Last Updated
March 20, 2024
Record last verified: 2024-03